Eligible patients will be randomized in a ratio of 2:1 to receive either chemotherapy (a
taxane and a platinum compound) plus CPG 7909 Injection or chemotherapy alone. Protocol
therapy will be administered until disease progression or intolerable toxicity. CpG 7909
Injection will be administered subcutaneously, on Weeks 2 and 3 of each three-week cycle
(days 8 and 15) and chemotherapy will be administered on Week 1 (Day 1). Patients will
undergo complete disease evaluation at the end of every other treatment cycle until disease
progression.